核桃仁泥外敷治疗肌肉注射后皮下硬结的疗效观察

采用核桃仁泥外敷治疗１３８例（实验组）肌肉注射后皮下硬结，并与４０例（对照组）采用新鲜土豆片外敷硬结法比较。结果表明：实验组患者治疗１５天后Ⅰ度和Ⅱ度硬结治愈率分别为８１．１３％和４２．２５％，总有效率达９２．０３％，明显优于对照组（Ｐ＜０．００１）。     

The “Biplanar” forehead lift

A new technique of forehead rhytidectomy is presented that combines the best features of the coronal incision with those of the anterior hairline incision. The plane of dissection is formed by an anterior subcutaneous plane dissecting a lateral subgaleal plane. This approach is particularly valuable in patients with high foreheads, severe static wrinkling, and asymmetrical eyebrows.Presented in part at the Annual Meeting of the American Society of Aesthetic Plastic Surgeons, Boston, MA, 1984     

猪门静脉回流阻断模型内毒素的移位

【目的】拟在猪的肠血管阻断模型中探讨门静脉回流阻断肠淤血可能造成的内毒素移位和肿瘤坏死因子释放。【方法】采用种群相近体质量22～25kg雌性小猪8只，无感染症状。分离门静脉和肝后下腔静脉分别阻断、然后开放各60min．观察血压、心率，阻断前和开放60min各取回肠末端小肠全层行光镜、电镜检查，测定门、颈静脉血内毒素及肿瘤坏死因子（TNF—α）含量。【结果】门静脉和肝后下腔静脉阻断后，肠淤血、水肿，并随时间延长而加重，光镜检查表明实验后肠粘膜和腺体明显损伤，电镜检查表明细胞超微结构轻微异常。阻断前后的血内毒素、TNF—α含量无显著性差异。【结论】①肠静脉回流阻断60min引起的肠道淤血可导致肠粘膜屏障损伤。②在60min内肠淤血性的损伤不会引起肠腔内内毒素的大量移位及TNF—α的释放。     

止血带致皮下出血并休克的不良反应1例报告

患者,男,64岁,以“左手掌皮下条索状硬结10年,加重伴小指屈曲畸形1年”于2005年12月6日入院。查:左手掌第五掌指关节处皮肤皱褶,皮下一纵行挛缩带如弓弦样感,使第五掌指关节呈屈曲90°位畸形,严重影响功能和外观。诊断为左手掌腱膜挛缩症。无高血压、冠心病及糖尿病史,心电图正常,肝肾功能、血常规和血凝化验均在正常范围,于12月8日在臂丛麻醉下行掌腱膜松解切除植皮手术。常规应用电子气囊止血带,压力40kPa,定时60min,手术切开皮肤后即发现止血带失用,出血明显,约在止血带使用6min时,患者述疲乏不适,继而突然出现心率减慢(48次/min),血压下降(60/48mmHg)。麻醉师考虑与使用     

Effects of fexofenadine and desloratadine on subjective and objective measures of nasal congestion in seasonal allergic rhinitis

BACKGROUND: In vitro studies have shown much higher H1-receptor antagonist potency with desloratadine (DL) compared to fexofenadine (FEX), although it is unclear whether this has any clinical relevance on disease control parameters in seasonal allergic rhinitis (SAR), especially for nasal congestion. OBJECTIVE: To compare the relative efficacy between presently recommended doses of DL and FEX on daily measurements of peak nasal inspiratory flow (PNIF) and nasal symptoms in SAR. METHODS: Forty-nine patients with SAR were randomized into a double-blind, placebo-controlled cross-over study during the grass pollen season, comparing 2 weeks of once daily treatment with (a) 180 mg FEX or (b) 5 mg DL, taken in the morning. There was a 7-10 day placebo run-in and washout prior to each randomized treatment. Measurements were made in the morning (AM) and in the evening (PM) for PNIF (the primary outcome variable), nasal and eye symptoms. The average of AM/PM values were used for analysis. RESULTS: There were significant (P < 0.05) improvements, compared to placebo, with FEX and DL, for PNIF, nasal blockage, nasal irritation, and total nasal symptoms, but not nasal discharge or eye symptoms. There were no significant differences between active treatments. Values for PNIF (L/min) for mean placebo baseline, mean difference from baseline (95% CI for difference) were 126, 10 (4-16) for FEX; and 122, 11 (4-17) for DL. The mean difference (95% CI) between FEX vs. DL was 1 L/min (-7-8). Values for total nasal symptoms (out of 12) were: 3.2, 0.7 (0.2-1.2) for FEX; and 3.4, 0.9 (0.3-1.5) for DL, and for nasal blockage (out of 3) were: 1.1, 0.2 (0.1-0.4) for FEX; and 1.2, 0.3 (0.1-0.5) for DL. The mean difference (95% CI) in total nasal symptoms and nasal blockage between FEX vs. DL was 0.1 (-0.6-0.8) and 0.1 (-0.2-0.3), respectively. CONCLUSIONS: Recommended once daily doses of fexofenadine and desloratadine were equally effective in improving nasal peak flow and nasal symptoms in SAR.     

How do topical nasal corticosteroids improve sleep and daytime somnolence in allergic rhinitis?

Therapy for rhinitis improves sleep quality and symptoms of daytime sleepiness. This improvement with therapy may be secondary to anti-inflammatory effects, leading to a reduction of inflammatory mediators, or to a mechanical reduction of congestion directly leading to improvement in sleep disturbance. We combined our data from 3 placebo-controlled studies of intranasal corticosteroids in patients with perennial rhinitis to determine whether a correlation between the reduction of congestion and improved sleep and daytime somnolence existed. The pooled data of budesonide, flunisolide, and fluticasone demonstrated significantly decreased nasal congestion, sleep problems, and sleepiness in treated patients. The data demonstrated a correlation between a reduction in nasal congestion and an improvement of sleep (P < .01) and daytime somnolence (P = .01). Thus, topical intranasal corticosteroids should be used to decrease nasal congestion and to improve sleep and daytime somnolence in patients manifesting these symptoms.     

Altered chromatin landscape in circulating T follicular helper and regulatory cells following grass pollen subcutaneous and sublingual immunotherapy

1. Download : Download high-res image (285KB)
2. Download : Download full-size image